✦ LIBER ✦
8544 A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM)
✍ Scribed by Zhao, Y.; Liao, H.; Hou, X.; Sun, J.; Guo, Y.; Li, S.; Zhang, L.
- Book ID
- 122671270
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 47 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.